drugset / Trial / NCT05352347
Phase 2b/3 Trial of NuSepin® in COVID-19 Pneumonia Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
A Randomized, Double-blinded, Placebo-controlled, Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID-19 Pneumonia Patients
Timeline
- Start
- 2022-04-12
- Primary completion
- 2024-11-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | NuSepin® | Unknown | 0.2 mg/kg | Intravenous |
| Comparator | NuSepin® | Unknown | 0.4 mg/kg | Intravenous |